Recently, researchers tested the drug, called “olaparib,” in a clinical trial with whom are men with prostate cancer. People with prostate cancer tend to have a mutation in one of several genes that are involved in BRCA1 and BRCA2. Both these genes are considered damaged DNA genes. These genes in prostate cancer are also similarly shown in other cancers like breast and ovarian cancer. Since these genes from prostate cancer are similar to other cancers, researchers use the drug Olaparib that is is used to treat breast and ovarian cancer to test it out. Olaparib is a PARP inhibitor. This drug blocks the PARP enzyme that repairs broken DNA. It acts against cancer. The clinical trials involved with 400 men with prostate cancer show that tumors did shrink by 2.3% compared to those men with prostate cancer that use standard therapy. After one year of testing and using olaparib, about 22% show no signs of processing cancer, while on the other hand, those that use standard treatment show 13.5 %. Olaparib drugs are currently being tested and are not FDA approved for prostate cancer use yet.
This is a notable finding of how drugs that there is hope for men with prostate cancer that there is treatment in the future that can help them with their health. This article was fascinating to read because I noticed that the FDA only approves olaparib drugs for breast and ovarian cancers, and not prostate cancer. Then I thought about how the drugs might be involved with hormones. The reason I thought about this is that breast and ovarian cancers are female, and prostate cancer is for men.